Skip to main content
KYTX
NASDAQ Life Sciences

Updated Miv-cel Data at EULAR Shows Substantial Reduction in Refractory RA

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.1
Mkt Cap
$480.282M
52W Low
$2.52
52W High
$13.67
52W Position info
221% above low
Off High info
41% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

KYTX has more than doubled off its 52-week low of $2.52.

Summary

Kyverna Therapeutics presented updated Phase 1 data for its lead candidate, miv-cel, at the EULAR 2026 Congress, demonstrating a substantial reduction in disease activity in ACPA-positive, treatment-refractory rheumatoid arthritis patients. The data showed a majority of patients achieved ACR70 response by Week 36 and evidence of an immune reset. This positive update reinforces miv-cel's broad potential across autoimmune diseases, following recent strong data in myasthenia gravis and a BLA submission for Stiff Person Syndrome. The results further validate the drug's mechanism and expand its potential market opportunity in a difficult-to-treat patient population. The Phase 2 portion of the COMPARE trial, comparing miv-cel to rituximab, is fully enrolled.

At the time of this announcement, KYTX was trading at $8.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $480.3M. The 52-week trading range was $2.52 to $13.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KYTX - Latest Insights

KYTX
Oct 23, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $4.64 info
Change: -$0.790 (-15%) info
Market Cap: $285.098M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $4.64 info
Change: -$2.41 (-34%) info
Market Cap: $285.098M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.19
Real-time Price: $4.64 info
Change: -$2.55 (-35%) info
Market Cap: $285.098M info
KYTX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.02
Real-time Price: $4.64 info
Change: -$3.38 (-42%) info
Market Cap: $285.098M info
KYTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $4.64 info
Change: -$3.38 (-42%) info
Market Cap: $285.098M info